How Will the Complex Interplay Between Efficacy, Safety, and Delivery Impact Retinal Specialists’ Preferences for and Payers’ Acceptance of Current and Emerging Therapies? Diabetic macular…
Which Key Attributes Will Drive Physician Prescribing and Formulary Inclusion of Current and Emerging PAH Therapies? Pulmonary arterial hypertension (PAH) is a severe, progressive, debilitating…
Payer and Physician Perspectives on the Role of New Biologics and Biosimilars for Moderate to Severe Inflammatory Bowel Disease Moderate to severe inflammatory bowel disease (IBD) patients who…
Where Are the Remaining Areas of Opportunity for Emerging Non-TNF Biologics and Oral Agents in the Increasingly Crowded Psoriatic Arthritis Market? The availability of tumor necrosis factor alpha…
Physician and Payer Attitudes and the Impact of the Aging Population Aging is considered a new healthcare challenge globally, and Alzheimer’s disease (AD) is one of the most debilitating…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA…
LaunchTrends: Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor…
In This Underserved Arena, What Clinical Attributes Will Be Most Persuasive for Neurologists and Payers Regarding Novel Outpatient Rescue Therapies? Acute repetitive seizures (ARS)—also known as…
Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Endocrinologists and Payers Expect of New and Emerging Therapies? The evidence demonstrating the serious physical, economic,…
What Attributes of Emerging Therapies Will Most Influence Both Physicians’ and Payers’ Decisions to Effectively Position These Biologics Against IV Belimumab? Systemic lupus erythematosus (SLE…
How Will the Rise in Antibiotic Resistance Shape the U.S. Prescribing and Reimbursement Environment for Novel Antibiotics? Although antibiotics from several drug classes are available to treat…
How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…
Payer and Physician Receptivity to Oral HIF-PH Inhibitors and Other Novel Treatments: Which Emerging Drugs Excite Them? Renal anemia is one of the primary complications of chronic kidney disease (…
In a Market of Entrenched, Effective, and Mostly Generic Therapies, Where Do Physicians and Payers Identify Areas for Differentiation? The prevalence of Parkinson’s disease (PD) will approach 3…
Compared with Current and Emerging Non-Insulin Therapies, Does Metformin’s Clinical Profile Justify Its Dominant Position in Recommended Treatment Guidelines? Affecting 30 million people in the…